Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 1—January 2004

Dispatch

Antifungal Susceptibilities of Cryptococcus neoformans

Lennox K. Archibald*1Comments to Author , Marion J. Tuohy†, Deborah A. Wilson†, Okey Nwanyanwu‡, Peter N. Kazembe‡, Somsit Tansuphasawadikul§, Boonchuay Eampokalap§, Achara Chaovavanich§, L.Barth Reller¶, William R. Jarvis*, Gerri S. Hall†, and Gary W. Procop†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Cleveland Clinic Foundation, Cleveland, Ohio, USA; ‡Lilongwe Central Hospital, Lilongwe, Malawi; §Bamrasnaradura Hospital, Nonthaburi, Thailand; ¶Duke University Medical Center, Durham, North Carolina, USA

Main Article

Table 2

Percentage of Cryptococcus neoformans isolates susceptible at each MIC dilution

% Susceptible
MICs (μg/mL) U.S. isolates Thailand isolates Malawi isolates
Amphotericin B
0.5 3
1 50 72 31
2 100 100 100
Fluconazole
1 5
2 30
4 40 21 25
8 90 83 87
16 100 100 94
32 100
Itraconazole
0.016 5
0.030 15 14 50
0.060 75 93 87
0.125 10 100 100
5 Flucytosine
1 6
2 5 7 12
4 60 72 69
8 100 100 94
16 100
Ketoconazole
<0.008 5
0.016 20 12
0.030 35 14 62
0.060 90 79 75
0.125 95 93 81
0.250 100 100 100

Main Article

1 Present address: Regeneration Technologies, Inc., Alachua, Florida, USA.

TOP